



**Figure 1** HEPES-mediated intracellular delivery of anti-STIP1 antibodies inhibits viability and increases toxicity in different cell lines. Control IgG2 antibodies (Ctrl IgG), anti-STIP1 antibodies (STIP1 Ab) (Abnova; Cat. No: H00010963-M02); STIP1-(M02) or anti-STIP1 antibodies (STIP1 Ab) (Abnova; Cat. No: H00010963-M35): STIP1-(M35) were initially mixed with 20mM HEPES 15 min before intracellular delivery. Antibodies were subsequently delivered into (A) ovarian cancer ES2 (B) non-cancerous cells-immortalized human endometrial stromal Cells (HESC). After 24–48 h of incubation, cell viability (24 h) and cytotoxicity (48 h) were analyzed with the MTT and LDH assays, respectively. (C) ES2 and HESC cells were cultured for 24 h. The cell lysates were then collected and the level of STIP1 (Santa Cruz Biotechnology, Dallas, TX, USA) was quantified in the ES2 and HESC cells by western blotting. Antibodies against actin served as controls (housekeeping). Error bars indicate the standard errors of the mean (n = 3). \*p < 0.05.